This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grimshaw, M. J. Articles by Balkwill, F. R. Search for Related Content PubMed PubMed Citation Articles by Grimshaw, M. J. Articles by Balkwill, F. R.

Cancer Research United Kingdom Translational Oncology Laboratory, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London EC1M 6BQ, [M. J. G., F. R. B.], and Oxford BioMedica United Kingdom Ltd., Oxford OX4 4GA [S. N.], United Kingdom

Endothelins (ETs) are a group of vasoactive peptides (ET-1, ET-2 and ET-3) produced by many cell types that bind to G-protein-linked transmembrane receptors, ET-A receptors (ET-RAs) and ET-B receptors (ET-RBs). These peptides are expressed in several human tumors, including carcinomas of the breast, and have a mitogenic effect in ovarian cancer cell lines. We investigated ET expression in infiltrating ductal carcinomas (IDCs) of the breast and the relationship between ET and hypoxia. ET staining was increased in human grade II IDC samples compared with normal breast tissue. ET-2 and ET-RB mRNA expression were absent in the majority of normal human breast samples (1 of 5 and 0 of 5, respectively) but was present in the majority of IDC tested (13 of 15 and 12 of 15, respectively). In a murine breast cancer model, HTH-K, ET-2, and ET-RB mRNA were detected in tumor but not normal breast tissue, and ET expression colocalized with areas of hypoxia. In vitro, ET-2, ET-RA, and ET-RB mRNA were increased by incubating HTH-K cells in hypoxia (0.1% oxygen) for 24 h. Hypoxia also up-regulated ET-2 mRNA in several human breast tumor cell lines. ET-2 mRNA increased within 3 h in a hypoxia-inducible factor 1-dependent manner. The ET-RB antagonist BQ-788 increased in hypoxia-associated apoptosis of breast tumor cells in vitro. These effects could be reversed by addition of ET-2 peptide. Intratumoral injection of BQ-788 led to an increase in the development and extent of necrosis within the HTH-K tumor and a decrease in the rate of tumor growth. The ET-RA antagonist, BQ-123, also led to a decrease in tumor growth but without a concomitant increase in necrosis. We propose that modulation of ET-2 production via the hypoxia-inducible factor 1 transcription factor and autocrine signaling via ET-RB is a novel mechanism by which tumor cells can withstand hypoxic stress. Treatment of breast carcinomas with ET receptor antagonists may have a therapeutic benefit.

This article has been cited by other articles:

				C. Guruvayoorappan Tumor Versus Tumor-Associated Macrophages: How Hot is the Link? Integr Cancer Ther, June 1, 2008; 7(2): 90 - 95. [Abstract] [PDF]

				G. M Tse, B. Chaiwun, K.-M. Lau, R. Scolyer, C S. Lee, R. Z Karim, T. C Putti, B. K Law, P. C Lui, and P. H. Tan Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours J. Clin. Pathol., September 1, 2007; 60(9): 1051 - 1056. [Abstract] [Full Text] [PDF]

				M J Grimshaw Endothelins and hypoxia-inducible factor in cancer Endocr. Relat. Cancer, June 1, 2007; 14(2): 233 - 244. [Abstract] [Full Text] [PDF]

				J. L. Wilson, J. Burchell, and M. J. Grimshaw Endothelins Induce CCR7 Expression by Breast Tumor Cells via Endothelin Receptor A and Hypoxia-Inducible Factor-1 Cancer Res., December 15, 2006; 66(24): 11802 - 11807. [Abstract] [Full Text] [PDF]

				J. M. Hearnes, D. J. Mays, K. L. Schavolt, L. Tang, X. Jiang, and J. A. Pietenpol Chromatin Immunoprecipitation-Based Screen To Identify Functional Genomic Binding Sites for Sequence-Specific Transactivators Mol. Cell. Biol., November 15, 2005; 25(22): 10148 - 10158. [Abstract] [Full Text] [PDF]

				S. Takizawa, T. Uchide, J. Adur, T. Kozakai, E. Kotake-Nara, J. Quan, and K. Saida Differential expression of endothelin-2 along the mouse intestinal tract J. Mol. Endocrinol., October 1, 2005; 35(2): 201 - 209. [Abstract] [Full Text] [PDF]

				B. Z. Olenyuk, G.-J. Zhang, J. M. Klco, N. G. Nickols, W. G. Kaelin Jr., and P. B. Dervan Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist PNAS, November 30, 2004; 101(48): 16768 - 16773. [Abstract] [Full Text] [PDF]

				C. Murdoch, A. Giannoudis, and C. E. Lewis Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood, October 15, 2004; 104(8): 2224 - 2234. [Abstract] [Full Text] [PDF]

				M. J. Grimshaw, T. Hagemann, A. Ayhan, C. E. Gillett, C. Binder, and F. R. Balkwill A Role for Endothelin-2 and Its Receptors in Breast Tumor Cell Invasion Cancer Res., April 1, 2004; 64(7): 2461 - 2468. [Abstract] [Full Text] [PDF]

				P. Wulfing, C. Kersting, J. Tio, R.-J. Fischer, C. Wulfing, C. Poremba, R. Diallo, W. Bocker, and L. Kiesel Endothelin-1-, Endothelin-A-, and Endothelin-B-Receptor Expression Is Correlated with Vascular Endothelial Growth Factor Expression and Angiogenesis in Breast Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2393 - 2400. [Abstract] [Full Text] [PDF]